Tepnel Diagnostics extends major supply agreement of its cystic fibrosis screening kits
French Cystic Fibrosis Screening Programme renews its agreement to purchase kits for a further three years
Tepnel Life Sciences PLC has been awarded a three year extension to its current Supply Agreement to provide ELUCIGENE(tm) DNA testing kits to the "Association Française pour le Dépistage et la Prevention des Handicaps de l'Enfant (AFDPHE)". In 2002 the French government funded a national neo-natal screening programme which screens every newborn in France for cystic fibrosis, a debilitating and usually fatal disease. A contract to supply ELUCIGENE(tm) kits to the AFDPHE was originally signed in April 2002 and under this latest extension is effective until April 2009.
Early identification of the disease can ensure that the appropriate treatment and support is provided to the child and its parents. All newborns in France (approximately 800,000 p.a.), are pre-screened for raised levels of immuno-reactive trypsin (IRT). Newborns that exhibit a high level of IRT are further screened by DNA testing to confirm the disease.
These DNA tests are exclusively performed with the ELUCIGENE(tm) CF30 testing kit developed by Tepnel Diagnostics to test for the 30 most frequent Cystic Fibrosis mutations in the French population.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
An international study proposes stool analysis for early detection of pancreatic cancer - A genetic signature of 27 microorganisms in stool defines the high-risk population for pancreatic ductal adenocarcinoma
Opening the cavity floodgates - Biochemists investigate the transport of large proteins through bacterial cell membranes
Watermelon genome decoded - Decoded genome paves way for better watermelons
BIO White Paper Dispels Over-Patenting Myth - Patenting is a Critical Element in Fostering Research and Development
Dow acquires Rohm and Haas, creating world's leading specialty chemicals and advanced materials company - $18.8 billion transaction marks pivotal point in Dow's transformation
Cells stop dividing when this gene kicks into high gear
Targeted test for antibiotic resistance in clinical Enterobacter species - New discovery enables targeted antibiotic therapy
Varian, Inc. Announces Unique Probe Technology Breakthrough for Biological Solids NMR
Breakthrough Discovery Sheds Light on Heart and Muscle Health - Scientists shoot first true-to-life 3D image of the thick filament of mammalian heart muscle
Diagnosis just a breath away with new laser
MIT nanotubes sniff out cancer agents in living cells - Chemical engineers use carbon nanotubes to monitor chemotherapy, detect toxins at the single-molecule level
